[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"keratinocyte-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:keratinocyte-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100593765","phase-1-treating-basal-and-squamous-cell-carcinomas-with-fractional-laser-and-tirbanibulin-ointment-100593765",false,"NCT07010692","Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment","Using Fractional Lasers and Tirbanibulin Ointment to Treat Keratinocyte Carcinomas","Inclusion Criteria: biopsy confirmed squamous and\u002For basal cell carcinoma not previously treated by another method.\n\nExclusion Criteria:\n\n* Cannot be pregnant at the time of treatment","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.",[27,28,29,30],"Keratinocyte Carcinoma","Basal Cell Carcinomas","Squamous Cell Carcinoma","Skin Cancer",[32,29,33,34,35,36,37],"Basal Cell Carcinoma","BCC","SCC","keratinocyte carcinoma","skin cancer","laser treatment","RECRUITING","2025-09-15",{"date":41,"type":42},"2025-09-17","ACTUAL",{"date":44,"type":42},"2025-05-16",{"date":46,"type":20},"2030-06",{"name":48,"class":49},"Bruce Robinson, MD","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100512705","phase-3-nicotinamide-chemoprevention-for-keratinocyte-carcinoma-in-solid-organ-transplant-recipients---pivotal-trial-100512705","NCT05955924","Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial","Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: a Multicentre, Pragmatic Randomized Trial","SPRINTR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Kidney, liver, heart, or lung transplant at least two years ago\n* History of at least one prior histologically-confirmed keratinocyte carcinoma or squamous cell carcinoma in situ\n* Currently immunosuppressed with a calcineurin inhibitor-based regimen (cyclosporine or tacrolimus)\n* Able to attend follow-up visits\n\nExclusion Criteria:\n\n* Use of nicotinamide or niacin (≥250 mg daily) within past 12 weeks\n* Untreated localized skin cancer at baseline (patient can enrol after skin cancer treatment)\n* Biopsy-confirmed acute rejection episode within the past 12 weeks\n* Active liver disease (high AST \\>3 times or bilirubin \\>1.5 times)\n* Severe kidney disease (estimated glomerular filtration rate \\\u003C20 mL\u002Fmin\u002F1.73 m2)\n* Solid organ or hematologic malignancy, invasive melanoma, Merkel cell carcinoma, or metastatic skin cancer within the past five years\n* Pregnancy or lactation\n* Need for ongoing carbamazepine or primidone\n* Allergy to nicotinamide or any ingredient of the vitamin or placebo capsules",{"count":60,"type":20},396,[62],"PHASE3","As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. Skin cancer is now a leading cause of illness and disfigurement after kidney, liver, heart, and lung transplantation. Given the increased risk and burden of skin cancer in transplant recipients, prevention is critical.\n\nNicotinamide is a form of Vitamin B3 that has been shown to protect against skin cancer in the general population. However, it is unclear whether nicotinamide is effective among immune-suppressed transplant recipients. Investigators will conduct a clinical trial involving multiple transplant centres in Canada to evaluate whether oral nicotinamide (500 mg twice daily) is effective and safe for preventing skin cancer. Investigators will recruit 396 high-risk adult kidney, liver, heart, and lung transplant patients who have previously had at least one skin cancer. Patients will receive nicotinamide or sham tablets for up to 4 years. The results will inform efforts to improve the long-term health of transplant recipients.",[65,66,67,27],"Non-melanoma Skin Cancer","Carcinoma, Squamous Cell","Carcinoma, Basal Cell","2025-02-20",{"date":70,"type":42},"2025-02-21",{"date":72,"type":42},"2023-08-28",{"date":74,"type":20},"2027-08",{"name":76,"class":49},"Women's College Hospital",7]